Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze

Executive Summary

With Haegarda holding a convenience edge over Cinryze for HAE prophylaxis, Shire now has data showing that SHP616 also offers significant prevention of HAE attacks. How ‘616 fits into Shire’s overall HAE strategy is unclear.


Related Content

With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring
Mum On Takeda, Shire Outlines Two-Division Performance
Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio
Better Together: BioCryst, Idera Merge To Improve Rare Disease Position
Shire Will Cut Manufacturing Sites As It Looks For More Baxalta Synergies
Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy
CSL Behring Nears Market With Easier-To-Administer HAE Prophylactic


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts